Pharmaceutical
Technology
Health

Titan Pharmaceuticals

$1.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (2.25%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell TTNP and other stocks, options, ETFs, and crypto commission-free!

About

Titan Pharmaceuticals, Inc. Common Stock, also called Titan Pharmaceuticals, is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Read More Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Employees
13
Headquarters
South San Francisco, California
Founded
1992
Market Cap
70.07M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
748.51K
High Today
$1.88
Low Today
$1.78
Open Price
$1.78
Volume
101.76K
52 Week High
$6.90
52 Week Low
$1.03

Collections

Pharmaceutical
Technology
Health
Biopharmaceutical
Therapy
Medical
US
North America

News

PR Newswire10h

Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results On April 1, 2019

SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2018 financial results will be released after market close on Monday, April 1, 2019. Titan will host a live conference call to discuss the financial results and provide a general business review the following day, April 2, 2019, at 8:30 a.m. ET / 5:30 a.m. PT. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe DeVarney, Ph.D., exec...

396
Seeking AlphaFeb 25

Titan Pharmaceuticals teams up with AllianceRX Walgreens Prime; shares up 65% premarket

Titan Pharmaceuticals (NASDAQ:TTNP) is up 65% premarket on executing a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment with Probuphine (buprenorphine) implant, for opioid use disorder (OUD) in eligible patients.

5,578

Earnings

-$0.20
-$0.15
-$0.09
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.